Humoral Immune Responses During SARS-CoV-2 MRNA Vaccine Administration in Seropositive and Seronegative Individuals

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2021 Jul 26

PMID 34304742

Citations 40

Authors

Elizabeth Fraley

Cas LeMaster

Eric Geanes

Dithi Banerjee

Santosh Khanal

Elin Grundberg

Rangaraj Selvarangan

Todd Bradley

Affiliations

Soon will be listed here.

Abstract

Background: The global pandemic of coronavirus disease 2019 (COVID-19) is caused by infection with the SARS-CoV-2 virus. Currently, there are three approved vaccines against SARS-CoV-2 in the USA, including two based on messenger RNA (mRNA) technology that has demonstrated high vaccine efficacy. We sought to characterize humoral immune responses, at high resolution, during immunization with the BNT162b2 (Pfizer-BioNTech) vaccine in individuals with or without prior history of natural SARS-CoV-2 infection.

Methods: We determined antibody responses after each dose of the BNT162b2 SARS-CoV-2 vaccine in individuals who had no prior history of SARS-CoV-2 infection (seronegative) and individuals that had previous viral infection 30-60 days prior to first vaccination (seropositive). To do this, we used both an antibody isotype-specific multiplexed bead-based binding assays targeting multiple SARS-CoV-2 viral protein antigens and an assay that identified potential SARS-CoV-2 neutralizing antibody levels. Moreover, we mapped antibody epitope specificity after immunization using SARS-CoV-2 spike protein peptide arrays.

Results: Antibody levels were significantly higher after a single dose in seropositive individuals compared to seronegative individuals and were comparable to levels observed in seronegative individuals after two doses. While IgG was boosted by vaccination for both seronegative and seropositive individuals, only seronegative individuals had increased IgA or IgM antibody titers after primary immunization. We identified immunodominant peptides targeted on both SARS-CoV-2 spike S1 and S2 subunits after vaccination.

Conclusion: These findings demonstrated the antibody responses to SARS-CoV-2 immunization in seropositive and seronegative individuals and provide support for the concept of using prior infection history as a guide for the consideration of future vaccination regimens. Moreover, we identified key epitopes on the SARS-CoV-2 spike protein that are targeted by antibodies after vaccination that could guide future vaccine and immune correlate development.

Citing Articles

Avidity maturation of anti-spike IgG after vaccination in COVID-19 convalescent vs COVID-19 naïve patients.

Lofstrom E, Eringfalt A, Kotz A, Tham J, Unden J APMIS. 2024; 133(1):e13489.

PMID: 39509082 PMC: 11650010. DOI: 10.1111/apm.13489.

Effectiveness of Pfizer Vaccine BNT162b2 Against SARS-CoV-2 in Americans 16 and Older: A Systematic Review.

Wilburn J, Sappe B, Jorge K, Hickey L, Nandyala D, Chadha T Cureus. 2024; 16(7):e65111.

PMID: 39171051 PMC: 11338298. DOI: 10.7759/cureus.65111.

Passive antibody transfer from pregnant women to their fetus are maximized after SARS-CoV-2 vaccination irrespective of prior infection.

Lauritsen C, Trinh I, Desai S, Clancey E, Murrell A, Rambaran S J Allergy Clin Immunol Glob. 2024; 3(1):100189.

PMID: 38268538 PMC: 10805668. DOI: 10.1016/j.jacig.2023.100189.

Effects of Antibodies in the Serum After the Administration of COVID Vaccines and Their Hematological and Cardiovascular Complications.

Haq M, Deshpande S Cureus. 2023; 15(10):e47984.

PMID: 38034236 PMC: 10686317. DOI: 10.7759/cureus.47984.

Dynamics of temporal immune responses in nonhuman primates and humans immunized with COVID-19 vaccines.

Ravindran R, Kang H, McReynolds C, Sanghar G, Chang W, Ramasamy S PLoS One. 2023; 18(10):e0287377.

PMID: 37856429 PMC: 10586671. DOI: 10.1371/journal.pone.0287377.

References

Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L . Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell. 2020; 182(1):73-84.e16. PMC: 7231725. DOI: 10.1016/j.cell.2020.05.025. View

Saadat S, Tehrani Z, Logue J, Newman M, Frieman M, Harris A . Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA. 2021; 325(14):1467-1469. PMC: 7922233. DOI: 10.1001/jama.2021.3341. View

Manisty C, Otter A, Treibel T, McKnight A, Altmann D, Brooks T . Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021; 397(10279):1057-1058. PMC: 7972310. DOI: 10.1016/S0140-6736(21)00501-8. View

Guo L, Wang Y, Kang L, Hu Y, Wang L, Zhong J . Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerg Microbes Infect. 2021; 10(1):664-676. PMC: 8023607. DOI: 10.1080/22221751.2021.1905488. View

Ebinger J, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko J . Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021; 27(6):981-984. PMC: 8205849. DOI: 10.1038/s41591-021-01325-6. View

Li Y, Lai D, Zhang H, Jiang H, Tian X, Ma M . Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell Mol Immunol. 2020; 17(10):1095-1097. PMC: 7475724. DOI: 10.1038/s41423-020-00523-5. View

Farrera-Soler L, Daguer J, Barluenga S, Vadas O, Cohen P, Pagano S . Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma. PLoS One. 2020; 15(9):e0238089. PMC: 7480855. DOI: 10.1371/journal.pone.0238089. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Mercado N, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J . Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020; 586(7830):583-588. PMC: 7581548. DOI: 10.1038/s41586-020-2607-z. View

10.

Li Y, Ma M, Lei Q, Wang F, Hong W, Lai D . Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. Cell Rep. 2021; 34(13):108915. PMC: 7953450. DOI: 10.1016/j.celrep.2021.108915. View

11.

Krammer F, Srivastava K, Alshammary H, Amoako A, Awawda M, Beach K . Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021; 384(14):1372-1374. PMC: 8008743. DOI: 10.1056/NEJMc2101667. View

12.

Bradley T, Grundberg E, Selvarangan R, LeMaster C, Fraley E, Banerjee D . Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021; 384(20):1959-1961. PMC: 8008753. DOI: 10.1056/NEJMc2102051. View

13.

Zamecnik C, Rajan J, Yamauchi K, Mann S, Loudermilk R, Sowa G . ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. Cell Rep Med. 2020; 1(7):100123. PMC: 7513813. DOI: 10.1016/j.xcrm.2020.100123. View

14.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

15.

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

16.

Asahi-Ozaki Y, Yoshikawa T, Iwakura Y, Suzuki Y, Tamura S, Kurata T . Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol. 2004; 74(2):328-35. DOI: 10.1002/jmv.20173. View

17.

Boudreau C, Yu W, Suscovich T, Talbot H, Edwards K, Alter G . Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination. J Clin Invest. 2019; 130(2):662-672. PMC: 6994146. DOI: 10.1172/JCI129520. View

18.

Suthar M, Zimmerman M, Kauffman R, Mantus G, Linderman S, Hudson W . Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Rep Med. 2020; 1(3):100040. PMC: 7276302. DOI: 10.1016/j.xcrm.2020.100040. View

19.

Feldstein L, Rose E, Horwitz S, Collins J, Newhams M, Son M . Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020; 383(4):334-346. PMC: 7346765. DOI: 10.1056/NEJMoa2021680. View

20.

Ng K, Faulkner N, Cornish G, Rosa A, Harvey R, Hussain S . Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020; 370(6522):1339-1343. PMC: 7857411. DOI: 10.1126/science.abe1107. View